Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6729276 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1979548 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6730282 | 0.73 | ALDH1A1 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL4936016 | 0.73 | KDM4E (0.48) | SMN1; SMN2HSD17B10CYP2D6CYP2C19TSHR | |
| SCHEMBL18125947 | 0.73 | KDM4E (0.48) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL2896474 | 0.72 | L3MBTL1 (0.34) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL1934610 | 0.71 | — | — | |
| SCHEMBL18340952 | 0.70 | CYP2D6 (0.37) | SMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL19561380 | 0.70 | CYP2D6 (0.48) | SMN1; SMN2HSD17B10CYP2D6CYP2C19TSHR | |
| SCHEMBL20269674 | 0.70 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-1219612-B1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | SMN1; SMN2 974/4885HSD17B10 1537/4885CYP2D6 859/4885 |
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | SMN1; SMN2 3031/4885HSD17B10 462/4885CYP2D6 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.